Tvardi Therapeutics
$3.22
0
+$0.07+2.06% Today
Statistics
Day High
3.22
Day Low
3.09
52W High
42.98
52W Low
2.85
Volume
23,178
Avg. Volume
-
Mkt Cap
30.21M
P/E Ratio
-
Dividend Yield
-
Dividend
-
Upcoming
Earnings
19MayExpected
Expected EPS
-0.744286
Actual EPS
N/A
Financials
-992.95%Profit Margin
Unprofitable14.27MRevenue
-141.73MNet Income
Analyst Ratings
3Average Price Target
The highest estimate is 3.00.
From 2 ratings within the last 6 months. This is not an investment recommendation.
From 2 ratings within the last 6 months. This is not an investment recommendation.
Buy 0%
Hold 50%
Sell 50%
People Also Follow
This list is based on the watchlists of people on Stock Events who follow TVRD. It's not an investment recommendation.
Competitors
This list is an analysis based on recent market events. It's not an investment recommendation.
Vertex Pharmaceuticals
VRTX
Mkt Cap112.22B
Teva- Pharmaceutical Industries
TEVA
Mkt Cap38.65B
Johnson & Johnson
JNJ
Mkt Cap564.35B
Abbvie
ABBV
Mkt Cap368.57B
Pfizer
PFE
Mkt Cap156.77B
Novartis
NVS
Mkt Cap293.34B
Merck
MRK
Mkt Cap294.39B
Gilead Sciences
GILD
Mkt Cap170.84B
Alkermes
ALKS
Mkt Cap5.7B
About
Tvardi Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of novel, oral, and small molecule therapies targeting signal transducer and activator of transcription 3 (STAT3) to treat inflammatory and proliferative diseases with significant unmet need in the United States. The company's lead product candidates include TTI-101, which is in Phase 1b/2 clinical development stage for fibrosis-driven diseases with an initial focus on idiopathic pulmonary fibrosis (IPF), and hepatocellular carcinoma (HCC); and TTI-109, an oral, small molecule STAT3 inhibitor which is in Phase-1 clinical trial stage. Tvardi Therapeutics, Inc. was founded in 2017 and is based in Sugar Land, Texas.
Show more...
CEO
Dr. Imran Alibhai Ph.D.
Employees
17
Country
United States
ISIN
US1407553072
Listings
0 Comments
Share your thoughts
FAQ
What is Tvardi Therapeutics stock price today?▼
The current price of TVRD is $3.22 USD — it has increased by +2.06% in the past 24 hours. Watch Tvardi Therapeutics stock price performance more closely on the chart.
What is Tvardi Therapeutics stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Tvardi Therapeutics stocks are traded under the ticker TVRD.
Is Tvardi Therapeutics stock price growing?▼
TVRD stock has fallen by -7.47% compared to the previous week, the month change is a -8.52% fall, over the last year Tvardi Therapeutics has showed a -83.48% decrease.
What is Tvardi Therapeutics market cap?▼
Today Tvardi Therapeutics has the market capitalization of 30.21M
When is the next Tvardi Therapeutics earnings date?▼
Tvardi Therapeutics is going to release the next earnings report on May 19, 2026.
What were Tvardi Therapeutics earnings last quarter?▼
TVRD earnings for the last quarter are -0.78 USD per share, whereas the estimation was -0.65 USD resulting in a -20.7% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Tvardi Therapeutics revenue for the last year?▼
Tvardi Therapeutics revenue for the last year amounts to 14.27M USD.
What is Tvardi Therapeutics net income for the last year?▼
TVRD net income for the last year is -141.73M USD.
How many employees does Tvardi Therapeutics have?▼
As of April 22, 2026, the company has 17 employees.
In which sector is Tvardi Therapeutics located?▼
Tvardi Therapeutics operates in the Health & Wellness sector.
When did Tvardi Therapeutics complete a stock split?▼
The last stock split for Tvardi Therapeutics was on April 16, 2025 with a ratio of 1:3.
Where is Tvardi Therapeutics headquartered?▼
Tvardi Therapeutics is headquartered in Sugar Land, United States.